ASK-Teva enteric-coated tablets 75 mg 3 blisters of 10 pcs.

Active ingredient: acetylsalicylic acid.

1 tablet contains 75 mg or 100 mg of acetylsalicylic acid.

Excipients: microcrystalline cellulose (type 102), corn starch, colloidal anhydrous silicon dioxide, stearic acid.

Shell: methacrylate copolymer dispersion, polysorbate 80, sodium lauryl sulfate, triethyl citrate, talc.

• Hypersensitivity to acetylsalicylic acid, other salicylates or any component of the drug.
• Chronic asthma caused by a history of salicylates or nonsteroidal anti-inflammatory drugs.
• Acute peptic ulcers.
• Hemorrhagic diathesis.
• Severe renal failure.
• Severe liver failure.
• Severe heart failure.
• Combination with methotrexate at a dose of 15 mg/week or more.

For oral use.

The tablets should be swallowed whole with sufficient liquid (1/2 glass of water). The tablets should not be crushed, cut or chewed, as the enteric coating of the tablet prevents the drug from irritating the intestines.

To reduce the risk of death in patients with suspected acute myocardial infarction, the drug should be used at a dose of 75-300 mg per day. For 30 days after the infarction, continue to take a maintenance dose of 75-300 mg per day. After 30 days, the issue of further prevention of recurrent myocardial infarction should be considered.

Pregnant women

Salicylates should be used with caution during the first and second trimesters of pregnancy. Salicylates are contraindicated during the third trimester of pregnancy.

Children

The medicine is not intended for use in children.

Drivers

No research was conducted.

Symptoms of severe poisoning may develop slowly, for example within 12-24 hours after administration. After oral administration of ASK doses up to 150 mg/kg body weight, moderate intoxication may develop, and at doses >300 mg/kg body weight, severe intoxication may develop.

Chronic salicylate poisoning can be latent because its symptoms are nonspecific. Moderate chronic intoxication is usually observed only after repeated ingestion of large doses.

Acute intoxication is indicated by a pronounced change in acid-base balance, which may vary depending on the age of the patient and the severity of intoxication. Its most common manifestation in children is metabolic acidosis. The severity of the condition cannot be assessed solely on the basis of the concentration of salicylates in the blood plasma. The absorption of acetylsalicylic acid may be slowed down due to delayed gastric release, the formation of concrements in the stomach or when the drug is taken in the form of enteric-coated tablets.

Spontaneous reports included information on other adverse reactions for all dosage forms of ASK, including during oral short-term and long-term therapy, therefore it is not possible to assign a frequency category according to CIOMS III.

Hemolysis and hemolytic anemia have been observed in patients with severe forms of glucose-6-phosphate dehydrogenase deficiency.

Due to its antiplatelet effect, the use of ASK may increase the risk of bleeding. Bleeding events such as perioperative bleeding, hematomas, epistaxis, urogenital bleeding, and gingival bleeding have been observed. Symptoms may persist for 4-8 days after discontinuation of acetylsalicylic acid.

Serious bleeding events, such as gastrointestinal bleeding and haemorrhagic stroke, have been observed rarely or very rarely, particularly in patients with uncontrolled hypertension and/or concomitant use of anticoagulants, which in some cases can be potentially life-threatening.

When used with methotrexate at doses of 15 mg/week or more, the hematological toxicity of methotrexate increases (due to a decrease in the renal clearance of methotrexate by anti-inflammatory agents and displacement of methotrexate from plasma protein binding by salicylates). Therefore, the simultaneous use of methotrexate (at doses >15 mg/week) with acetylsalicylic acid is contraindicated.

Store in a dry place, protected from light, at a temperature below 25 °C.

Keep out of reach of children.